
Kalliopi P Siziopikou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6553755/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. Journal of the National Cancer Institute, 2022, 114, 664-675.	6.3	31
2	Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges. Pathology Research and Practice, 2022, 230, 153753.	2.3	6
3	Abstract P1-02-11: Somatic alterations and PD-L1 positivity in advanced breast cancer. Cancer Research, 2022, 82, P1-02-11-P1-02-11.	0.9	1
4	Abstract PS2-08: Identification of incidental putative germline variants in circulating tumor DNA. , 2021, , .		0
5	Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: An institutional experience. Pathology Research and Practice, 2021, 222, 153441.	2.3	4
6	Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2367-2374.	1.6	16
7	Correlation of manual semi-quantitative and automated quantitative Ki-67 proliferative index with OncotypeDXTMÂrecurrence score in invasive breast carcinoma. Breast Disease, 2021, 41, 1-11.	0.8	2
8	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers, 2021, 13, 4910.	3.7	8
9	Landscape of circulating tumour DNA in metastatic breast cancer. EBioMedicine, 2020, 58, 102914.	6.1	40
10	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€L1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	142
11	The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast. American Journal of Clinical Pathology, 2019, 152, 169-176.	0.7	10
12	Double-Equivocal HER2 Invasive Breast Carcinomas: Institutional Experience and Review of Literature. Archives of Pathology and Laboratory Medicine, 2018, 142, 1511-1516.	2.5	4
13	Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Research and Treatment, 2018, 171, 371-381.	2.5	100
14	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.9	99
15	Phyllodes tumours of the breast: a consensus review. Histopathology, 2016, 68, 5-21.	2.9	329
16	BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association. BMJ Case Reports, 2015, 2015, bcr2014208830.	0.5	6
17	GATA-3 Expression in Ductal Carcinoma in situ (DCIS) of the Breast. American Journal of Clinical Pathology, 2014, 142, A250-A250.	0.7	Ο
18	Non–mass-associated intraductal papillomas: is excision necessary?. Human Pathology, 2014, 45, 583-588	2.0	25

KALLIOPI P SIZIOPIKOU

#	Article	IF	CITATIONS
19	Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes and Development, 2014, 28, 1191-1203.	5.9	193
20	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. Journal of the National Cancer Institute, 2014, 106, .	6.3	18
21	Ductal Carcinoma In Situ of the Breast: Current Concepts and Future Directions. Archives of Pathology and Laboratory Medicine, 2013, 137, 462-466.	2.5	61
22	What are NCI-designated cancer centers using for breast cancer HER2 testing?. Journal of Clinical Oncology, 2013, 31, 626-626.	1.6	1
23	Are oncologists involved in cancer biomarker decisions at their institutions?. Journal of Clinical Oncology, 2013, 31, 6617-6617.	1.6	1
24	Biomarker testing methods in breast, gastric, and lung cancers: A benchmarking survey of NCI cancer centers Journal of Clinical Oncology, 2013, 31, e22093-e22093.	1.6	2
25	Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer Journal of Clinical Oncology, 2012, 30, TPS1134-TPS1134.	1.6	2